According to Stock Market Ratings, the eleven analysts that are now following Allogene Therapeutics, Inc. (NASDAQ:ALLO) have recommended shares of the firm on average as “Moderate Buy.” Eight research experts have recommended that the business purchase the stock, while three have rated it with a hold rating. Brokers that have covered the stock over the past year have an average 12-month price objective of $15.29.
Recent comments on ALLO have come from a number of brokerages. In a research report released on Friday, January 19, HC Wainwright lowered their price target on Allogene Therapeutics shares from $12.00 to $10.00 and established a “buy” rating for the business. On Friday, January 5, JMP Securities reiterated its “market perform” recommendation for Allogene Therapeutics’ stock in a research note. Friday, December 8th marked the start of Citigroup’s research study covering shares of Allogene Therapeutics. They gave the business a “buy” rating and a $7.00 price target. In a research report released on Friday, January 5, Guggenheim reduced Allogene Therapeutics’ shares from a “buy” recommendation to a “neutral” one.
Also Read: When Is The Business Tax Filing Due for 2024?
Allogene Therapeutics: Insider Purchasing and Selling
In other Allogene Therapeutics news, on Monday, December 18, Director Deborah M. Messemer sold 18,640 shares of the company’s stock. A total of $50,328.00 was exchanged for the stock at an average price of $2.70. The director now directly owns 62,456 shares of the company, valued at about $168,631.20, as a result of the transaction. The SEC has made the sale public in a document that may be seen by clicking this URL. Insiders of the corporation hold 27.40 percent of the stock.
Expert Opinion Regarding Allogene Therapeutics: Institutional Investors
Hedge funds have adjusted their stakes in the company lately. During the second quarter, Oppenheimer & Co. Inc. invested $62,000 in new Allogene Therapeutics shares. In the second quarter, JPMorgan Chase & Co. increased its investment in Allogene Therapeutics by 22.1%. After purchasing 1,109,851 more shares of the company’s stock during the quarter, JPMorgan Chase & Co. now owns 6,134,395 shares valued at $30,488,000. In the second quarter, TD Asset Management Inc. increased its investment in Allogene Therapeutics by 14.9%. After purchasing 25,800 more shares of the company’s stock during the quarter, TD Asset Management Inc. now has 199,479 shares valued at $991,000. In the second quarter, Crosspoint Financial LLC acquired a new interest in Allogene Therapeutics for about $60,000. Lastly, in the third quarter, Harbour Capital Advisors Inc. increased its investment in Allogene Therapeutics by 18.0%. After purchasing an additional 10,473 shares of the company’s stock during the quarter, Harbour Capital Advisors Inc. now owns 68,519 shares valued at $217,000. Institutional investors now hold 78.51% of the stock.
Also Read: 2024 to bring some major changes filing taxes
Allogene Therapeutics Price Performance: NASDAQ ALLO’s shares opened Friday at $3.24. The 50-day simple moving average of the firm is $2.92, while the 200-day simple moving average is $3.47. With a market value of $545.23 million, the company has a -1.45 PE ratio and a 0.76 beta. In the past year, Allogene Therapeutics has seen lows of $2.23 and highs of $8.44.
The most recent quarterly earnings data for Allogene Therapeutics (NASDAQ:ALLO) were disclosed on Thursday, November 2. The firm exceeded the average expectation of ($0.53) by $0.16 when it announced ($0.37) earnings per share (EPS) for the quarter. Allogene Therapeutics had a 54.03% negative return on equity and a 178,954.28% negative net margin. In contrast to analyst projections of $0.05 million, the company’s revenue for the quarter was $0.04 million. Research analysts collectively predict that Allogene Therapeutics’ earnings per share for the current fiscal year will be -2.03.
Concerning Allogene Therapeutics
Genetically modified allogeneic T cell treatments are developed and marketed by Allogene Therapeutics, Inc., a clinical stage immuno-oncology business, to treat cancer. It creates, produces, and markets UCART19, a potential allogeneic chimeric antigen receptor (CAR) T cell therapy for treating adult and paediatric R/R CD19 positive B-cell ALL patients.
Is it currently a good time to buy $1,000 in Allogene Therapeutics?
You should know this before thinking about Allogene Therapeutics.
Every day, Wall Street’s top-rated and top-performing research analysts and the companies they advise to their customers are monitored. Allogene Therapeutics was not included in the list of the five stocks that leading analysts are subtly advising their customers to purchase before the market as a whole catches on.
Although analysts now rank Allogene Therapeutics as a “Moderate Buy,” they think these five companies are better investments.
Source:
https://www.marketbeat.com/instant-alerts/nasdaq-allo-consensus-analyst-rating-2024-01-28/
-
WWE Bad Blood 2024: Everything You Need to Know – Date, India Timings, Full Match Card, and How to Watch
WWE fans across the globe are eagerly awaiting the return of one of the most iconic pay-per-view events, WWE Bad Blood, which makes its triumphant comeback after two decades. Here’s everything you need to know about WWE Bad Blood 2024, including the match card, viewing options, and key event details. Event Overview Date: WWE Bad…
-
UNLV vs Syracuse Football Thriller – October 4, 2024
In a dramatic showdown on October 4, 2024, the Syracuse Orange narrowly defeated the UNLV Rebels 44-41 in overtime at Allegiant Stadium, Las Vegas. Both teams entered the game with matching 4-1 records, and the contest lived up to the hype with high-paced scoring and critical plays. First Quarter: Syracuse Takes Early Lead Syracuse took…
-
Joker 2’s Rotten Tomatoes Score: A Disappointing Turn for the Sequel?
Joker: Folie à Deux, the highly anticipated sequel to 2019’s Joker, has landed with less than stellar reviews, leaving fans and critics divided. Despite initial excitement, the Rotten Tomatoes score for the movie has raised concerns about its overall impact and reception. As of early October 2024, Joker 2 holds a disappointing Rotten Tomatoes score…
-
Student Loan Forgiveness Program from Biden Clarifies Legal Hurdles – Who Stands to Benefit?
In a significant legal victory for President Joe Biden’s administration, a federal judge recently lifted a block on Biden’s student loan forgiveness plan, clearing the way for millions of borrowers to receive relief. The latest iteration of this program, developed after the Supreme Court struck down an earlier attempt, aims to wipe out some or…
-
Europa League Showdown: How to Livestream Porto vs. Manchester United from Anywhere (2024)
The UEFA Europa League 2024 is heating up, and one of the marquee matchups sees FC Porto take on Manchester United at the iconic Estádio do Dragão. With both clubs eager to make their mark in the tournament, fans worldwide are eager to follow the action. Here’s a guide on how to stream this highly…
-
Better Man: Robbie Williams’ Biopic Trailer Promises an Unconventional and Emotional Journey
Robbie Williams’ much-anticipated biopic, Better Man, is set to take audiences on a surreal yet deeply emotional journey through his life, as revealed by the new trailer released on October 2, 2024. Directed by Michael Gracey, known for The Greatest Showman, the film offers an innovative take on the life of the British pop superstar,…
-
Champions League Soccer: How to Watch Slovan Bratislava vs. Manchester City Live From Anywhere
The UEFA Champions League match between Slovan Bratislava and Manchester City promises excitement, as City, the reigning English champions, travel to Slovakia. Taking place on October 1, 2024, at the Tehelne Pole Stadium in Bratislava, the game kicks off at 9:00 p.m. local time (3:00 p.m. Eastern Time). Where to Watch: Team News: Key Match…
-
Gavin Creel: Broadway and ‘American Horror Story’ Star Dies at 48 After Battle with Rare Cancer
Renowned Broadway actor Gavin Creel, aged 48, has tragically passed away following a brief yet fierce battle with a rare and aggressive form of cancer, metastatic melanotic peripheral nerve sheath sarcoma. Diagnosed in July 2024, Creel had been receiving treatment at New York’s Memorial Sloan Kettering before transitioning to hospice care. His death was confirmed…
Dwayne Paschke specializes in writing, management, development, design and Search Engine Optimization. Although he has worked for 8 years in the industry, he never found an ideal person to work with as a partner. Later, he found Sebastian Pearson, and they both found specific understanding between them. Both of them divided their tasks in this project and are running this venture successfully.